
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
LabCorp recently announced the company’s drug development business, Covance, has acquired GlobalCare, a globally recognized industry leader in patient-centric decentralized clinical trials support services.
This acquisition will expand Covance’s decentralized clinical trials capabilities globally, enabling recruitment and increasing access to trials. It will also benefit GlobalCare’s current and future customers by providing access to needed resources and technology to scale services to meet growing industry needs.
For more information, click






